Diffuse Large B-cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is sub-classified in to molecular subgroups that correspond to different stages of lymphocyte development- namely germinal center B-cell (GCB) and non- germinal center B-cell DLBCL (non-GCB).In Rituximab (R)-CHOP treatment settings other markers than immunohistochemical features predict the outcome of the DLBCL. In order to investigate the prediction value of the immunohistochemical GCB/non GCB classification of DLBCL of the outcome of DLBCL patients treated with the R-CHOP regimen a retrospective study was conducted. Results from this study support the studies that suggest that Rituximab eliminates or modulates the significance of some already established prognostic markers for DLBCL. In context of the modern therapy, previously recognized markers should be re-evaluated and new prognostic indicators for DLBL has to be identified

Autorentext

Ass.Sanja Trajkova MSc,was born in Skopje,Macedonia.She finished High Medical School,Faculty of Medicine in her hometown.From 2002 she works at University Clinic of Hematology,Skopje,Macedonia,as Specialist of Internal Medicine,and since 2012 she is Head of subunit for lymphoprolierative malignancies which are focus of her research.